Trop-2 in Upper Tract Urothelial Carcinoma

Trop-2 in Upper Tract Urothelial Carcinoma

Trophoblast cell surface antigen 2 (Trop-2, encoded by <i>TACSTD2</i>) is the target protein of sacituzumab govitecan, a novel antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma. However, the expression status of Trop-2 in upper tract urothelial carcinoma (UT...

Full description

Bibliographic Details
Main Authors:	Eisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, Ken Kuwahara, Takafumi Minami, Taigo Kato, Koji Hatano, Atsunari Kawashima, Motohide Uemura, Tetsuya Takao, Hiroaki Fushimi, Kotoe Katayama, Seiya Imoto, Kazuhiro Yoshimura, Ryoichi Imamura, Hirotsugu Uemura, Norio Nonomura
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Current Oncology
Subjects:	trophoblast cell surface antigen 2 <i>TACSTD2</i> upper tract urothelial carcinoma immunohistochemical analysis RNA sequencing sacituzumab govitecan
Online Access:	https://www.mdpi.com/1718-7729/29/6/312

Similar Items

Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus
by: Sascha Hoppe, et al.
Published: (2022-09-01)

Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes
by: Semir Vranic
Published: (2023-03-01)

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
by: Jae Ho Jeong, et al.
Published: (2022-12-01)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
by: Sara Bravaccini, et al.
Published: (2021-11-01)

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
by: Xiujuan Gui, et al.
Published: (2023-10-01)

Trop2 Expression in Extramammary Paget’s Disease and Normal Skin
by: Takamichi Ito, et al.
Published: (2021-07-01)

Efficacy and Safety of Sacituzumab Govitecan on Advanced HER2-negative Breast Cancer: A Meta-analysis
by: ZHANG Qian, et al.
Published: (2022-04-01)

Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
by: Jigang Chen, et al.
Published: (2021-10-01)

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
by: Giuliana Pavone, et al.
Published: (2021-12-01)

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
by: Jiazheng Yu, et al.
Published: (2023-07-01)

TROP2 Expression in Sebaceous and Sweat Gland Carcinoma
by: Takamichi Ito, et al.
Published: (2022-01-01)

Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
by: Roberta Caputo, et al.
Published: (2024-03-01)

Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
by: Stefano Testa, et al.
Published: (2023-09-01)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
by: Mythili Shastry, et al.
Published: (2022-12-01)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
by: Wensheng Liu, et al.
Published: (2023-11-01)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
by: Jiao Xie, et al.
Published: (2023-06-01)

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
by: Emanuele Perrone, et al.
Published: (2020-03-01)

Best of the year: Advanced breast cancer in 2023
by: Ilana Schlam, et al.
Published: (2024-04-01)

Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
by: Olga Bednova, et al.
Published: (2020-10-01)

Mechanisms of Resistance to Antibody-Drug Conjugates
by: Rita Khoury, et al.
Published: (2023-06-01)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
by: Yitian Lang, et al.
Published: (2023-04-01)

Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report
by: Pierluigi di Mauro, et al.
Published: (2023-02-01)

Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany
by: Amelie Wickmann, et al.
Published: (2024-03-01)

Editorial: Case reports in breast cancer : 2022
by: Nan Wang
Published: (2023-12-01)

Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles
by: Mary Anne Fenton, et al.
Published: (2023-11-01)

Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
by: Giuseppe Saltalamacchia, et al.
Published: (2024-02-01)

Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space
by: Atsuki Matsukawa, et al.
Published: (2021-07-01)

TROP2 Represents a Negative Prognostic Factor in Colorectal Adenocarcinoma and Its Expression Is Associated with Features of Epithelial–Mesenchymal Transition and Invasiveness
by: Jiří Švec, et al.
Published: (2022-08-01)

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
by: Demin Shi, et al.
Published: (2023-05-01)

Biological distinction between grades 2 and 3 with respect to intravesical recurrence in T1 high-grade bladder tumors: a retrospective study
by: Akinaru Yamamoto, et al.
Published: (2022-04-01)

Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma
by: Ramona Erber, et al.
Published: (2021-12-01)

Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma
by: Yuki Nishimura, et al.
Published: (2023-03-01)

Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma
by: Eisuke Tomiyama, et al.
Published: (2020-07-01)

Mucinous cystadenoma of the renal parenchyma presenting as a Bosniak IIF complex renal cyst
by: Takanori Nate, et al.
Published: (2023-03-01)

DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers
by: Olga Katzendorn, et al.
Published: (2021-04-01)

Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer
by: Yujiro Hayashi, et al.
Published: (2020-05-01)

TROP2 methylation and expression in tamoxifen-resistant breast cancer
by: Stephanie M. Zimmers, et al.
Published: (2018-07-01)

Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma
by: Taigo Kato, et al.
Published: (2021-01-01)

Fucosylation in Urological Cancers
by: Kazutoshi Fujita, et al.
Published: (2021-12-01)

TERT C228T mutation in non‐malignant bladder urothelium is associated with intravesical recurrence for patients with non‐muscle invasive bladder cancer
by: Yujiro Hayashi, et al.
Published: (2020-10-01)